American Journal of Psychiatry

Article	Citations
Highlights From the Residents’ Journal: December 2021	519
Treating Pathologies of the Will	223
Integrating Clinical and Basic Research: Opioid Use Disorder, Psychotic Illnesses, and Prefrontal Microcircuits Relevant to Schizophrenia	160
Evaluating Associations Between Cannabis and Heroin Use	149
Broadening the Parameters of Clinical High Risk for Psychosis	139
2024 Annual Meeting: Presidential Address	131
Effectiveness of Antipsychotic Use for Reducing Risk of Work Disability: Results From a Within-Subject Analysis of a Swedish National Cohort of 21,551 Patients With First-Episode Nonaffective Psychosi	125
Future of Sensorimotor and Psychomotor Dysfunction in Mental Disorders: Emerging Tools, Methodological Challenges, and the Road Ahead	124
A Call to Psychiatrists: Deprescription of Unnecessary Anticholinergic Medications in Schizophrenia Must Start Now	122
20-Year Prospective, Sequential Follow-Up Study of Heterogeneity in Associations of Duration of Untreated Psychosis With Symptoms, Functioning, and Quality of Life Following First-Episode Psychosis	111
A New Agenda for Optimizing Investments in Community Mental Health and Reducing Disparities	103
From Scanner to Bedside: Building Bridges in Translational Psychiatric Neuroimaging	102
Brain-Based Biotypes of Psychiatric Vulnerability in the Acute Aftermath of Trauma	102
Depression, Inflammation, and Postpartum Psychosis	101
From Prediction to Action: Moving Beyond Machine Learning to Implementing Evidence-Based Perinatal Mental Health Care	99
Neural Signatures of Pain Modulation in Short-Term and Long-Term Mindfulness Training: A Randomized Active-Control Trial	93
Cannabis and Brain Health: What Is Next for Developmental Cohort Studies?	91
Can Neuromelanin-Sensitive MRI Provide Insight Into the Dopaminergic Pathways Contributing to Substance Use?	86
Predicting Conversion to Psychosis: What Lies Beyond the Biomarkers?	86
Mental Health Disparities Research: An Introduction to New Directions	85
Intentional Drug Overdose Deaths in the United States	82
Project Harmony: A Meta-Analysis With Individual Patient Data on Behavioral and Pharmacologic Trials for Comorbid Posttraumatic Stress and Alcohol or Other Drug Use Disorders	80
On the Genetic and Environmental Relationship Between Suicide Attempt and Death by Suicide	77
Correcting Overestimations in Self-Harm Visit Data	74
Genes To Mental Health (G2MH): A Framework to Map the Combined Effects of Rare and Common Variants on Dimensions of Cognition and Psychopathology	74

Suicide and the Menstrual Cycle	72
An Innovative Approach to Extending the Antidepressant Effects of Intravenous Ketamine in Major Depression	68
Methamphetamine-Induced Psychosis and Schizophrenia: A Call for Special Attention: Response to Zhu et al.	68
Correction to Poirot et al.	67
Corrigendum to Morley et al.	64
Older Adults are at Heightened Risk of the Effects of Cannabis Use: Response to Walaszek	61
Familial Risk of Postpartum Psychosis	61
New Insights Into Psychotic Disorders	61
2024 Annual Meeting: CEO and Medical Director’s Address	61
Back to the Future: Esmethadone, the (Maybe) Nonopiate Opiate, and Depression	59
Highlights From the Residents’ Journal: September 2024	59
Coordinate Network Mapping: An Emerging Approach for Morphometric Meta-Analysis	58
Neural Responses to Intranasal Oxytocin in Youths With Severe Irritability	58
Trends in Prescription Stimulant, Opioid, and Benzodiazepine Use and Diversion in U.S. Adolescents	56
The First Large GWAS Meta-Analysis for Postpartum Depression	56
Similar Rates of Deleterious Copy Number Variants in Early-Onset Psychosis and Autism Spectrum Disorder	55
Reduced Threat-Related Neural Efficiency: A Possible Biomarker for Pediatric Anxiety Disorders	55
Schizophrenia Imaging Signatures and Their Associations With Cognition, Psychopathology, and Genetics in the General Population	54
Sensitivity of Schizophrenia Endophenotype Biomarkers to Anticholinergic Medication Burden	53
Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression	53
12-month Prevalence Estimates of Substance Use Disorders Using DSM-5 Versus DSM-IV Criteria Among U.S. Nonelderly Adults With Substance Use	53
Characterizing the Most Vulnerable Prefrontal Cortical Neurons in Schizophrenia	53
Durability of Effects of Cognitive Remediation on Cognition and Psychosocial Functioning in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials	52
Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial	50
Early Adversity and Development: Parsing Heterogeneity and Identifying Pathways of Risk and Resilience	48
Scientific Advances Relevant to Schizophrenia, Psychosis, and the Treatment of Methamphetamine Use Disorder	48
Points that Need Attention in Early Auditory Information Processing Research in Schizophrenia: Response to Lin and Hsieh	47
Rebecca W. Brendel, M.D., J.D., 149th President, 2022–2023	47
Aberrant Developmental Patterns of Gamma-Band Response and Long-Range Communication Disruption in Youths With 22q11.2 Deletion Syndrome	47
Proof-of-Principle Study on ECT Illustrates Challenges and Possible Merits of Using Polygenic Risk Scores to Predict Treatment Response in Psychiatry	47
The Safety of Pimavanserin for Parkinson’s Disease and Efforts to Reduce Antipsychotics for People With Dementia	46
Sexual Identity Continuity and Change in a U.S. National Probability Sample of Sexual Minority Adults: Associations With Mental Health and Problematic Substance Use	45
Genetic and Environmental Contribution to the Co-Occurrence of Endocrine-Metabolic Disorders and Depression: A Nationwide Swedish Study of Siblings	45
From Crisis to Action: Psychiatry’s Ethical Imperative to Defend Transgender People’s Rights, Dignity, and Access to Care	45
Comment on “Elevated C-Reactive Protein in Patients With Depression, Independent of Genetic, Health, and Psychosocial Factors: Results From the UK Biobank”	45
Shared and Specific Neural Correlates of Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder: A Meta-Analysis of 243 Task-Based Functional MRI Studies	43
Alcohol and the Etiology of Depression	41
Ketamine for Depression, but at What Cost? A Review of Ketamine’s Neurotoxic Effects From Preclinical and Human Studies	41
Sustained Efficacy of Stanford Neuromodulation Therapy (SNT) in Open-Label Repeated Treatment	41
The Neglected Role of Psychotherapy for Treatment-Resistant Depression	40
Predictive Value of Acute Neuroplastic Response to rTMS in Treatment Outcome in Depression: A Concurrent TMS-fMRI Trial	39
Associations Between a Primary Care-Delivered Alcohol-Related Brief Intervention and Subsequent Opioid-Related Outcomes	38
2021 Articles of Import and Impact	37
Risk of Incident Psychosis and Mania With Prescription Amphetamines	37
Suicide in Black Females	37
Slowly Working Toward More Treatments for Depression in Bipolar II Disorder	36
Treatment Response Prediction in Major Depressive Disorder Using Multimodal MRI and Clinical Data: Secondary Analysis of a Randomized Clinical Trial	36
What Do Four Decades of Research Tell Us About the Association Between Childhood Adversity and Psychosis: An Updated and Extended Multi-Level Meta-Analysis	36
Risk of Experiencing an Overdose Event for Patients Undergoing Treatment With Medication for Opioid Use Disorder	35
Synaptic Variability and Cortical Gamma Oscillation Power in Schizophrenia	35

Reduction in Trauma-Related Symptoms After Anesthetic-Induced Intra-Operative Dreaming	35
Psilocybin: From Psychiatric Pariah to Perceived Panacea	35
Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression	35
Neural Correlates of Stress and Alcohol Cue-Induced Alcohol Craving and of Future Heavy Drinking: Evidence of Sex Differences	34
Predicting Acute Changes in Suicidal Ideation and Planning: A Longitudinal Study of Symptom Mediators and the Role of the Menstrual Cycle in Female Psychiatric Outpatients With Suicidality	34
Diagnosing Prescription Opioid Use Disorder in Patients Using Prescribed Opioids for Chronic Pain	34
Double-Blind, Sham-Controlled Randomized Trial Testing the Efficacy of fMRI Neurofeedback on Clinical and Cognitive Measures in Children With ADHD	34
Neuromodulation Strategies for the Treatment of Depression	34
The American Psychiatric Association Practice Guideline for the Treatment of Patients With Eating Disorders	33
Psychotherapy in Psychedelic Treatment: Safe, Evidence-Based, and Necessary	33
Can Smartphone-Based Support Apps Add Value to the Treatment of Opioid Use Disorder?	33
Drug Cues Trigger Corticolimbic Hyperreactivity in Heroin Users	32
Correction to Baum et al.	32
Harnessing the Power of Population Cohorts to Study the Relationship Between Endocrine-Metabolic Disorders and Depression	31
Setting the Record Straight on Long-Term Use, Dose Escalation, and Potential Misuse of Prescription Benzodiazepines	31
Keeping Track and Providing Tools for Future Crisis Management: Suicide Attempt and Self-Harm Presentations at Emergency Departments	31
The Association of Childhood Maltreatment and Mental Health Problems: Partly Causal and Partly Due to Other Factors	31
Differences in Social Determinants of Health Underlie Racial/Ethnic Disparities in Psychological Health and Well-Being: Study of 11,143 Older Adults	31
Beneath the Phenotypic Surface: Pleiotropy Shapes the Co-Occurrence of Alcohol Use Disorder and Psychopathology	30
A Case of Prolonged Mania, Psychosis, and Severe Depression After Psilocybin Use: Implications of Increased Psychedelic Drug Availability	30
Racial and Ethnic Biases and Psychiatric Misdiagnoses: Toward More Equitable Diagnosis and Treatment	30
When Will There Be Good News?	30
A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial	30
Toward Precision Noninvasive Brain Stimulation	30
Psychiatric Diagnoses in Parents and Psychiatric, Behavioral, and Psychosocial Outcomes in Their Offspring: A Swedish Population-Based Register Study	30
Innovative Directions to Advance Mental Health Disparities Research	29
Evaluating the Evidence for Brain-Based Biotypes of Psychiatric Vulnerability in the Acute Aftermath of Trauma	29
Psychological Support for Psilocybin Treatment: Reply to Letters on Our Commentary	29
The Amygdala and Depression: A Sober Reconsideration	29
Mortality Among Parkinson’s Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries	29
Interindividual Differences in Cortical Thickness and Their Genomic Underpinnings in Autism Spectrum Disorder	28
Auditory Steady-State Responses Probe GABA-Related Oscillatory Cortical Circuits and Their Relation to Neurodevelopmental Mental Disorders	27
Guilt by Association: Inflammation and Shared Genetic Risk Between Stress-Related and Immune Disorders	26
Correction	26
Highlights From the Residents’ Journal: December 2024	25
Understanding the Effects of Combined Lisdexamfetamine and Cognitive Behavior Therapy for Adults With Binge Eating Disorder	25
Drugs and Addiction Science: NIDA Celebrates 50 Years of Research and Looks to the Future	25
2024 Articles of Import and Impact	25
Ketamine After Two Antidepressants?	25
Neuromelanin-Sensitive MRI: A Biomarker for Treatment-Resistant Schizophrenia?	24
Progress and Challenges in GxE Research on Depression	24
Recommendations for the Usage of Ketamine and Esketamine	24
Ketamine and Esketamine for Treatment-Resistant Depression: Response to Reus, Mattes, and Schatzberg	24
Longitudinal Trajectory of the Link Between Ventral Striatum and Depression in Adolescence	23
Converging Evidence for Frontopolar Cortex as a Target for Neuromodulation in Addiction Treatment	23
Meta-Analyses of Genome-Wide Association Studies for Postpartum Depression	23
Functional Connectivity Mapping for rTMS Target Selection in Depression	23
Adolescent Suicidality and Depression, Premenstrual Dysphoric Disorder, and Safety Issues Related to Ketamine and Esketamine Treatment	23
Cannabis Use and the Endocannabinoid System: A Clinical Perspective	23
REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial	23
Associations Between General and Specific Mental Health Conditions in Young Adulthood and Cardiometabolic Complications in Middle Adulthood: A 40-Year Longitudinal Familial Coaggregation Study of 672,	23
Current and Future Approaches to Pediatric Anxiety Disorder Treatment	22
Shared and Unique Changes in Brain Connectivity Among Depressed Patients After Remission With Pharmacotherapy Versus Psychotherapy	22
Technology and Mental Health: State of the Art for Assessment and Treatment	22
Can Two 90-Minute Workshops Reduce Risk of Substance Use Disorder for Vulnerable Seventh Graders? Results and Scalability From the Co-Venture Trial	21
Perinatal Mental Health: Advances and Opportunities	21
Vaccines as Immunotherapies for Substance Use Disorders	21
Does Xanomeline/Trospium Have Unique Benefits for Cognitive Impairment Associated With Schizophrenia? Response to Tandon	21
Antidepressants and Bipolar Disorder: The Plot Thickens	21
Relapse in Schizophrenia: A Systematic Review of Criteria for Clinical Studies and International Consensus Guidelines to Improve Them	21
Rethinking the First Episode of Schizophrenia: Identifying Convergent Mechanisms During Development and Moving Toward Prediction	21
Pathogenic Variants and Ascertainment: Neuropsychiatric Disease Risk in a Health System Cohort	20
Understanding the Efficacy and Mechanism of Action of a Dextromethorphan-Bupropion Combination: Where Does It Fit in the NMDA Versus mu-Opioid Story?	20
Prevalence and Penetrance of Rare Pathogenic Variants in Neurodevelopmental Psychiatric Genes in a Health Care System Population	20
Improved Response Inhibition Through Cognition-Guided EEG Neurofeedback in Men With Methamphetamine Use Disorder	20
Late-Life Depression, Antidepressant Treatment, and Cognition: The Short Haul and the Long Haul	20
Psychotropic Drug–Related Weight Gain and Its Treatment	20
Highlights From the Residents’ Journal: September 2023	20
Recapitulation of Perturbed Striatal Gene Expression Dynamics of Donors’ Brains With Ventral Forebrain Organoids Derived From the Same Individuals With Schizophrenia	20
Healing, Harms, and Humility: Expanding the Scope of Psychedelic-Assisted Psychotherapy Research	20
An Insula-Enriched Regulator of Retinoic Acid Marks a New Intersection in the Neural Circuitry of Mouse Social Behavior	19
Varenicline as a First-Line Treatment for Individuals With Current Major Depressive Disorder Who Smoke Cigarettes	19
Neuropsychiatric Symptoms of Subacute and Chronic Long COVID	18
Irremediable Psychiatric Suffering, a Potential Indication for Psilocybin Treatment	18
Effects of County-Level Opioid Dispensing Rates on Individual-Level Patterns of Prescription Opioid and Heroin Consumption: Evidence From National U.S. Data	18
Focusing on Substance Use Disorders, Opioids, and Craving	18
Don’t Throw the Baby Out With the Bathwater: A Need for Nuanced Practice and Additional Research on Telehealth Management of ADHD	18
Increased Inflammation in Depression: A Little in All, or a Lot in a Few?	18
Neglect of Adverse Effects in Treatment Guidelines for Depression	18
Clozapine’s High Incidence of Ileus and Pneumonia Demand Better Clinical Strategies—How Do We Get There?	18

Polygenic Risk Scores and Genetics in Psychiatry	18
The Devastating Clinical Consequences of Child Abuse and Neglect: Increased Disease Vulnerability and Poor Treatment Response in Mood Disorders	17
Estimating Multimodal Structural Brain Variability in Schizophrenia Spectrum Disorders: A Worldwide ENIGMA Study	17
Reports to the Membership	17
Intermittent Theta Burst Stimulation With Adjunctive D-Cycloserine for Obsessive-Compulsive Disorder: A Randomized Clinical Trial	17
Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia	17
Disclosure of Editors’ Financial Relationships	17
Impact of COVID-19 Telehealth Policy Changes on Buprenorphine Treatment for Opioid Use Disorder	17
MORE Is Less Pain and Less Opioid Misuse: A Mindful Remedy	17
Putting Genetics to Work in the Psychiatric Clinic	17
Highlights From the Residents’ Journal: June 2025	16
New Insights Into Major Depression and the Treatment of Bipolar Depression	16
Intergenerational Effects of the Fast Track Intervention on Next-Generation Child Outcomes: A Preregistered Randomized Clinical Trial	16
Xanomeline-Trospium Treatment of Cognitive Impairments of Schizophrenia: Hope for Some, or Hope for All?	16
Affective Disorders, Pharmacogenomics, and Psychiatric Illness-Related Cardiometabolic Problems	16
Beyond the Landmarks: Where to Next With Biomarkers of Autism?	16
Prospective Associations Between Structural Brain Development and Onset of Depressive Disorder During Adolescence and Emerging Adulthood	15
Association Between Polygenic Risk Scores and Outcome of ECT	15
An Honest Reckoning With the Amygdala and Mental Illness	15
Treating Depression With Repetitive Transcranial Magnetic Stimulation: A Clinician’s Guide	15
Psychosis Risk With Prescription Amphetamine	15